H. Doubre

1.4k total citations
33 papers, 629 citations indexed

About

H. Doubre is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, H. Doubre has authored 33 papers receiving a total of 629 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Pulmonary and Respiratory Medicine, 25 papers in Oncology and 3 papers in Surgery. Recurrent topics in H. Doubre's work include Lung Cancer Treatments and Mutations (24 papers), Lung Cancer Research Studies (13 papers) and Cancer Immunotherapy and Biomarkers (10 papers). H. Doubre is often cited by papers focused on Lung Cancer Treatments and Mutations (24 papers), Lung Cancer Research Studies (13 papers) and Cancer Immunotherapy and Biomarkers (10 papers). H. Doubre collaborates with scholars based in France, Luxembourg and United States. H. Doubre's co-authors include C. Chouaïd, Florian Guisier, C. Decroisette, L. Falchero, M. Pérol, R. Lamy, P. Fournel, F. Viñas, Henri Janicot and Catherine Daniel and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and International Journal of Cancer.

In The Last Decade

H. Doubre

31 papers receiving 615 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
H. Doubre France	12	524	372	113	81	62	33	629
Jin‐Ji Yang China	13	458 0.9×	316 0.8×	138 1.2×	120 1.5×	44 0.7×	83	574
Vincent Fallet France	14	538 1.0×	472 1.3×	103 0.9×	85 1.0×	35 0.6×	45	679
Rinat Galiulin United States	6	388 0.7×	370 1.0×	135 1.2×	110 1.4×	39 0.6×	7	556
V. Gorbounova Russia	3	397 0.8×	359 1.0×	124 1.1×	95 1.2×	46 0.7×	7	516
Sook Jung Jo South Korea	6	724 1.4×	692 1.9×	171 1.5×	112 1.4×	86 1.4×	8	865
Laura Capelli Italy	12	402 0.8×	346 0.9×	153 1.4×	189 2.3×	90 1.5×	32	613
C. Blajman Argentina	9	425 0.8×	446 1.2×	186 1.6×	94 1.2×	51 0.8×	15	759
Yi-Sheng Huang China	11	589 1.1×	471 1.3×	140 1.2×	162 2.0×	36 0.6×	27	728
Paloma Martín-Martorell Spain	11	190 0.4×	279 0.8×	82 0.7×	52 0.6×	37 0.6×	30	426
A. Chemaissani Germany	9	508 1.0×	464 1.2×	124 1.1×	37 0.5×	35 0.6×	13	650

Countries citing papers authored by H. Doubre

Since Specialization

Citations

This map shows the geographic impact of H. Doubre's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H. Doubre with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H. Doubre more than expected).

Fields of papers citing papers by H. Doubre

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by H. Doubre. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H. Doubre. The network helps show where H. Doubre may publish in the future.

Co-authorship network of co-authors of H. Doubre

This figure shows the co-authorship network connecting the top 25 collaborators of H. Doubre. A scholar is included among the top collaborators of H. Doubre based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with H. Doubre. H. Doubre is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Monnet, Isabelle, Charles Ricordel, L. Bigay-Gamé, et al.. (2025). Rebiopsy Feasibility and Clinical Impact on Metastatic Non-Small-Cell Lung Cancer With EGFR/ALK/ROS Oncogenic Driver Progression After Optimal Targeted Therapy: A Multicenter Real-World Analysis. Clinical Lung Cancer. 26(8). e724–e730.

Doubre, H., I. Monnet, R. Azarian, et al.. (2024). Plasma tissue factor activity in lung cancer patients predicts venous thromboembolism and poor overall survival. Research and Practice in Thrombosis and Haemostasis. 8(2). 102359–102359. 2 indexed citations

Jamme, Philippe, Jean‐Baptiste Assié, Rémi Veillon, et al.. (2023). Real-World Treatment Outcomes of MET Exon14 Skipping in Non-small Cell Lung Cancer: GFPC 03-18 Study. Targeted Oncology. 18(4). 585–591. 3 indexed citations

Descourt, R., H. Doubre, C. Decroisette, et al.. (2023). Clinical Characteristics of Patients with Advanced ALK-Translocated Non-small Cell Lung Cancers and Long-Term Responses to Crizotinib (CRIZOLONG GFPC 05-19 Study). Targeted Oncology. 18(6). 905–914. 2 indexed citations

Doubre, H., Laurent Greillier, Charles Ricordel, et al.. (2023). Venous thrombotic events and impact on outcomes in patients treated with first-line single-agent pembrolizumab in PD-L1 ≥ 50% advanced non small cell lung cancer. Journal of Cancer Research and Clinical Oncology. 149(16). 15095–15102. 2 indexed citations

Descourt, R., Laurent Greillier, M. Pérol, et al.. (2022). First-line single-agent pembrolizumab for PD-L1-positive (tumor proportion score ≥ 50%) advanced non-small cell lung cancer in the real world: impact in brain metastasis: a national French multicentric cohort (ESCKEYP GFPC study). Cancer Immunology Immunotherapy. 72(1). 91–99. 18 indexed citations

Doubre, H., Élisabeth Longchampt, Diane Damotte, et al.. (2021). ALK Rearrangement in Lung Neuroendocrine Neoplasms: Case Series of Non-Asian Patients With Response to ALK Inhibitors. Clinical Lung Cancer. 22(5). e686–e690. 5 indexed citations

Assié, Jean‐Baptiste, I. Monnet, Marie-Ange Massiani, et al.. (2020). Durable responses to immunotherapy of non-small cell lung cancers harboring MET exon-14–skipping mutation: A series of 6 cases. Lung Cancer. 150. 21–25. 39 indexed citations

Baldacci, Simon, Benjamin Besse, Virginie Avrillon, et al.. (2020). 1303P Lorlatinib for advanced ALK+ non-small cell lung cancer (NSCLC): Efficacy and safety data from IFCT-1803 LORLATU expanded access program (EAP) cohort. Annals of Oncology. 31. S843–S843. 1 indexed citations

10.

Guisier, Florian, Catherine Dubos‐Arvis, F. Viñas, et al.. (2020). Efficacy and Safety of Anti–PD-1 Immunotherapy in Patients With Advanced NSCLC With BRAF, HER2, or MET Mutations or RET Translocation: GFPC 01-2018. Journal of Thoracic Oncology. 15(4). 628–636. 215 indexed citations

11.

Auliac, J.B., Pascal Dô, S. Bayle, et al.. (2019). Non-Small Cell Lung Cancer Patients Harboring HER2 Mutations: Clinical Characteristics and Management in a Real-Life Setting. Cohort HER2 EXPLORE GFPC 02–14. Advances in Therapy. 36(8). 2161–2166. 11 indexed citations

12.

Monnet, I., Marie-Ange Massiani, Jean‐Baptiste Assié, et al.. (2019). MA03.09 Dramatic Responses to Immune Checkpoint Inhibitors in MET Exon 14 Skipping Mutation (METex14mut) Non Small Cell Lung Cancers. Journal of Thoracic Oncology. 14(10). S259–S259. 2 indexed citations

13.

Auliac, J.B., M. Pérol, David Planchard, et al.. (2018). P1.13-09 Efficacy and Tolerance of Osimertinib in Real Word Setting: Results of the French Early Access Program (EXPLORE T790M GFPC Study). Journal of Thoracic Oncology. 13(10). S585–S585. 1 indexed citations

14.

Auliac, J.B., M. Pérol, David Planchard, et al.. (2018). Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation. Lung Cancer. 127. 96–102. 31 indexed citations

15.

Auliac, J.B., S. Bayle, A. Vergnenègre, et al.. (2018). Patients with Non-Small-Cell Lung Cancer Harbouring a BRAF Mutation: A Multicentre Study Exploring Clinical Characteristics, Management, and Outcomes in a Real-Life Setting: EXPLORE GFPC 02-14. Current Oncology. 25(5). 398–402. 7 indexed citations

16.

Corre, R., R. Gervais, Florian Guisier, et al.. (2017). Octogenarians with EGFR-mutated non-small cell lung Cancer (NSCLC) treated by Tyrosine Kinase Inhibitor (TKI): A multicentric real world study assessing tolerance and efficacy. OCTOMUT study GFPC 07-15. Annals of Oncology. 28. v485–v485. 1 indexed citations

17.

Fallet, Vincent, Jacques Cadranel, H. Doubre, et al.. (2014). Prospective screening for ALK: Clinical features and outcome according to ALK status. European Journal of Cancer. 50(7). 1239–1246. 39 indexed citations

18.

Mellot, François, S. Friard, H. Doubre, et al.. (2011). Le traitement par radiofréquence des tumeurs pulmonaires. Revue de Pneumologie Clinique. 67(4). 238–243. 3 indexed citations

19.

Doubre, H., Sandra Chantot‐Bastaraud, Martine Antoine, et al.. (2004). Multidrug resistance-associated protein (MRP1) is overexpressed in DNA aneuploid carcinomatous cells in non-small cell lung cancer (NSCLC). International Journal of Cancer. 113(4). 568–574. 24 indexed citations

20.

Fizazi, Karim, P Soulié, A. Fandi, et al.. (2000). Combination raltitrexed (Tomudex®)–oxaliplatin: a step forward in the struggle against mesothelioma? The Institut Gustave Roussy experience with chemotherapy and chemo-immunotherapy in mesothelioma. European Journal of Cancer. 36(12). 1514–1521. 40 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact